Beta-adrenergic blockade and traumatic brain injury: protective?

Area of Science:

• Trauma Surgery
• Neurocritical Care
• Pharmacology

Background:

• Catecholamine surge post-traumatic brain injury (TBI) correlates with increased infectious morbidity and mortality.
• Beta-adrenergic blockade (BB) has shown protective effects in TBI patients.
• Hypothesis: Suppressing catecholamine surge with BB in multiply injured TBI patients reduces mortality.

Purpose of the Study:

• To investigate the protective effect of beta-adrenergic blockade (BB) on mortality in patients with traumatic brain injury (TBI).

Main Methods:

• Retrospective query of trauma registry for blunt TBI patients (2003-2007).
• Identification of patients receiving more than one dose of beta-blockers (BB) via pharmacy records.
• Multivariable logistic regression analysis adjusted for age, injury severity, and other factors to assess BB's protective effect.

Main Results:

• 2,601 blunt TBI patients identified; 506 (20%) received BB.
• Despite higher age and injury severity in the BB group, mortality rates were similar (15% vs. 16%).
• Multivariable analysis revealed BB use was protective, reducing mortality by 65% (OR 0.347; CI 0.246-0.490).

Conclusions:

• Beta-blocker (BB) administration is associated with significantly reduced mortality in TBI patients.
• This simple, cost-effective intervention shows potential for substantial impact on TBI patient outcomes.
• Further prospective studies are recommended to confirm these findings.